Background Both vascular disease and elevated concentrations in plasma of plasminogen activator inhibitor type-1 (PA-1) are prominent in patients with non-insulin-dependent diabetes mellitus (NIDDM). We and others have hypothesized that the increased PAI-1 may contribute to acceleration of atherosclerosis in this condition and in other states characterized by insulin resistance as well. Surprisingly, however, elevations of PAI-1 decrease when type II diabetic patients are treated with exogenous insulin, as do circulating concentrations of the precursor of insulin, proinsulin, in plasma. Accordingly, the increased PAI-1 in patients with NIDDM may reflect effects of precursors of insulin rather than or in addition to those of insulin itself. To assess this possibility directly, this study was performed to identify potential direct effects of proinsulin and proinsulin split products on synthesis of PAI-1 in liver cells, thought to be the major source of circulating
Background Both vascular disease and elevated concentrations in plasma of plasminogen activator inhibitor type-1 (PA-1) are prominent in patients with non-insulin-dependent diabetes mellitus (NIDDM). We and others have hypothesized that the increased PAI-1 may contribute to acceleration of atherosclerosis in this condition and in other states characterized by insulin resistance as well. Surprisingly, however, elevations of PAI-1 decrease when type II diabetic patients are treated with exogenous insulin, as do circulating concentrations of the precursor of insulin, proinsulin, in plasma. Accordingly, the increased PAI-1 in patients with NIDDM may reflect effects of precursors of insulin rather than or in addition to those of insulin itself. To assess this possibility directly, this study was performed to identify potential direct effects of proinsulin and proinsulin split products on synthesis of PAI-1 in liver cells, thought to be the major source of circulating PAI-1 in vivo.
Methods and Results Hep G2 cells (highly differentiated human hepatoma cells) were exposed to human proinsulin, des (31, 32) proinsulin and des(64,65)proinsulin (split products of N i 'on-insulin-dependent (type II) diabetes mellitus (NIDDM) and other conditions associated with insulin resistance, such as hypertension and obesity, are characterized by accelerated vascular disease.1 We and others have hypothesized that one factor that may be responsible is reduced plasma fibrinolytic activity,2'3 which may shift the balance between thrombosis and fibrinolysis toward thrombosis4 and consequently increase exposure of luminal surfaces of vessel walls to clot-associated mitogens. Attenuated fibrinolysis attributable to increased concentrations of plasminogen activator inhibitor type-1 (PAT-1) in plasma, the primary physiological inhibitor of endogenous fibrinolysis, is a risk factor for deep vein thrombosis,S premature coronary artery disease,6-9 acute myocardial infarction,10-'2 and restenosis after percutaneous transluminal coronary angioplasty. 13 The "hyperinsulinemia" typically seen in patients with NIDDM reflects contributions to the assayed material, immunoreactive insulin (IRI), not only of insulin but also proinsulin), or C-peptide. Accumulation of PAI-1 in conditioned media increased in a time-and concentration-dependent fashion in response to the two des-intermediates [3.3- Conclusions Our results are consistent with the hypothesis that precursors of insulin (proinsulin and proinsulin split products), known to be present in relatively high concentrations in plasma in patients with NIDDM and conditions characterized by insulin resistance, may directly stimulate PAI-1 synthesis, thereby attenuating fibrinolysis and acceler-of proinsulin split product precursors of insulin that are detected in the conventional assays used.14 Split products such as des (31, 32) (Fig 1) . After 24 hours and at all subsequent intervals, PAI-1 was significantly increased with exposure of the cells to proinsulin or to des (31, 32) proinsulin and des(64,65)proinsulin. The two proinsulin split products elicited an increase in PAI-1 that persisted for up to 60 hours with a "rapid" increase occurring between 12 and 36 hours (from 4 to 45 and from 3 to 50 ng/mL, respectively) and a more modest increase seen between 36 and 60 hours (from 45 to 60 and from 50 to 70 ng/mL, Effects of Proinsulin, des(31,32)Proinsulin, des(64,65)Proinsulin, and C-Peptide on PAI-1 Activity After cells had been incubated with 10 nmol/L proinsulin, 10 nmol/L des(31,32)proinsulin, 10 nmol/L des(64,65)proinsulin, 10 nmol/L C-peptide, or vehicle alone for 24 and 48 hours, respectively, conditioned media were harvested and assayed for PAI-1 activity (n=3 for each condition). PAI-1 activity was low in each case (Table 1) , although values were somewhat higher in cells exposed to the proinsulin split products. The dichotomy between activity and concentration of PAI-1 protein in conditioned media is consistent with rapid conversion of PAI-1 to a latent form and to inactive (cleaved) forms in conditioned media of cultured cells in the absence of exogenous vitronectin (t/2 <2 hours at 370C).24 Effects of Proinsulin, des(31,32)Proinsulin, and des(64,65)Proinsulin on PAI-1 Synthesis Metabolic labeling of Hep G2 cells was performed to determine whether the precursors of insulin stimulated synthesis as well as secretion of PAI-1. The midpoint of the interval of incubation with labeled methionine corresponded to the 24-and 48-hour interval after the addition of proinsulin, des (31, 32) proinsulin, or des(64,65) proinsulin (10 nmol/L each, n=6 each for conditioned media, n=3 each for cell lysates).
As shown in Fig 4, Table 2) .
Mediation of Observed Effects by Insulin Receptors
To determine whether the effects observed were mediated in whole or in part by insulin receptors, a Cycloheximide, an inhibitor of protein synthesis, suppressed the stimulation by the agonists used, supporting the concept that changes in the accumulation of PAI-1 protein in conditioned media reflect changes in the rate of PAI-1 synthesis. Actinomycin D, an inhibitor of transcription, suppressed the stimulation as well supporting the concept that the effects of insulin precursors are mediated in part at the level of gene expression.
monoclonal antibody against an epitope on the a-subunit of the insulin receptor capable of inhibiting the binding of insulin to its receptor yet not acting as a partial agonist or autophosphorylating the receptor was used. Hep G2 cells were exposed to 10 nmol/L concentrations of each agonist for 24 hours with 0, 1, 5, or 10 ,ug/mL of the insulin receptor antibody (n=3 for each condition). Insulin (10 nmol/L) was used as a control.
The insulin receptor antibody inhibited the increased accumulation of PAI-1 protein in conditioned media completely when proinsulin was the agonist and almost completely (86%) when des (31, 32) proinsulin was the agonist (Fig 6) . With des(64,65)proinsulin, the inhibition was 68%. Inhibition was even greater than that seen with insulin (47%). Thus, effects of the precursors of insulin appeared to be mediated, largely or exclusively, through the insulin receptor. This interpretation is corroborated by our finding that stimulation by the precursors was not additive to that induced by insulin. In FIG 6 . Bar graph of plasminogen activator inhibitor type-1 (PAl-i) protein measured in the conditioned media of highly differentiated human hepatoma cells (Hep G2) exposed to 10 nmol/L concentrations of insulin, proinsulin, des (31, 32) proinsulin, or des(64,65) proinsulin for 24 hours in the presence of increasing concentrations of a monoclonal antibody to the insulin receptor.
Thus, "hyperinsulinemic" patients may, in fact, be insulin deficient.40 In view of these considerations, it is of particular interest that plasma PAI-1 declines (sic) in patients with type II diabetes given exogenous insulin, perhaps because concentrations in plasma of proinsulin and other precursors of insulin decline as stimulation of the pancreatic/-cells by hyperglycemia declines. In fact, concentrations of PAI-1 in plasma in type II diabetic patients correlate with concentrations of proinsulin and des (31, 32) proinsulin rather than with concentrations of insulin per se. 18 The markedly (up to 18-fold) increased frequency of cardiovascular events observed when proinsulin was administered to patients for at least 1 year17 is consistent with a deleterious effect of hyperproinsulinemia on fibrinolysis mediated by increased PAI-1. Under such conditions, the concentration of proinsulin in plasma in the proinsulin-treated patients was as high as 8 nmol/L, a concentration similar to that used in the present study.
The results of the present study are consistent with the hypothesis that both the increased risk of cardiovascular disease associated with insulin resistance and "hyperinsulinemia" (defined in terms of increased IRI) and the association of increased PAI-1 with increased IRI may be attributable, in part, to effects of precursors of insulin on the fibrinolytic system and specifically on PAI-1 synthesis. They are consistent with the dichotomy between plasma PAI-1 in patients with NIDDM who are given exogenous insulin compared with plasma PAI-1 in those who are not18 and with the parallel changes in plasma PAI-1 and plasma proinsulin seen in patients with NIDDM not given exogenous insulin. They are consistent also with the possibility that precursors of insulin may contribute to vascular disease by impairing fibrinolysis, consequently increasing exposure of vessel walls to intermittent platelet activation and release of platelet-and clot-associated mitogens. They suggest that reduction of atherogenesis in patients with NIDDM and in those with other conditions characterized by insulin resistance may be possible by suppression of elaboration of precursors of insulin or by pharmacologic antagonism of the direct effects of precursors of insulin on PAI-1 synthesis. 
